- Fluidigm Corporation is a leading global developer of life sciences instruments and consumables for use in research, diagnostics, and clinical applications.
- Fluidigm designs, manufactures, and markets a variety of instruments, consumables, reagents, and software from its two major technologies, CyTOF® Technology and Microfluidics Technology.
- Fluidigm is in a less-than-stellar financial position with only 1-2 years of cash runway dragged down by a higher-than-average cash burn of -$43M (TTM ended March 2021).
- Revenues aren't expected to grow too promisingly with FYE 2020 reaching $131.4M (+13% y/y) and analyst expectations of only 2% CAGR until 2023.
- In summary, the author projects Fluidigm Corporation as a "hold".
For further details see:
Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point